Nigel Ray
Vorstandsvorsitzender bei Angarus Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jian Li | F | 53 | 24 Jahre | |
Terrence Blaschke | M | 81 | 18 Jahre | |
Chih Ping Liu | M | - |
Angarus Therapeutics, Inc.
Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | - |
Judy Joice | F | 67 | 17 Jahre | |
Mark Smith | M | - |
Angarus Therapeutics, Inc.
Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | - |
Ling Yin Li | M | - |
Angarus Therapeutics, Inc.
Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | - |
Wei Qi Lin | M | - | 16 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Thomas A. Schreck | M | 67 | 7 Jahre | |
Matt Hogan | M | 64 | 12 Jahre | |
Michael Arenberg | M | 54 | 23 Jahre | |
David Hoffmann | M | 79 | 21 Jahre | |
Steven C. Halladay | M | 76 | 4 Jahre | |
Simon Benito | M | 79 | 17 Jahre | |
Paula V. Mendenhall | M | 80 | 7 Jahre | |
Jon Saxe | M | 88 | 19 Jahre | |
Michael D. Casey | M | 78 | 9 Jahre | |
Michael Chang | M | - |
Limerick BioPharma, Inc.
Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | - |
Armand P. Neukermans | M | 83 | - | |
Jeffrey P. Miller | M | 71 | 2 Jahre | |
Barbara J. Floy Laidlaw | M | - | 2 Jahre | |
David Abraham | M | 58 | 2 Jahre | |
Su Il Yum | M | 84 | - | |
Peter J. Langecker | M | 73 | 3 Jahre | |
Timothy Nelson | M | 60 | 7 Jahre | |
Arthur Tipton | M | 64 | 3 Jahre | |
Tai Wah Chan | M | 79 | - | |
Michael J. Taylor | M | 70 | - | |
Ted Broman | M | - | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 28 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen